If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive ...

The new US indication for Trelegy is for ... inhaler used across the company’s portfolio of inhaled COPD drugs. It was first approved in September last year for the long-term, once-daily ...

9. Ohtuvayre (ensifentrine) for COPD: Approved June 26, the inhaled medication is the first new type of maintenance COPD drug in over a decade. 10. Wakix (pitolisant) for pediatric narcolepsy ...

That includes the approval of "innovative" drugs like Tryvio for high blood pressure, Neffy for severe allergic reactions and Dupixent for chronic obstructive pulmonary disease (COPD), which all ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Although these products might confer significant advantages over the currently available treatments, there is still a huge unmet need for drugs that prevent the progression of COPD. Companies are ...

When it was approved by the FDA in June ... moderate or severe exacerbations among COPD patients. Amgen and AstraZeneca have hopes for their asthma drug Tezspire as a potential COPD treatment.

Specifically, the new definition emphasized the heterogeneity of COPD in terms of its underlying ... and that may soon have ...